-Angela Coxon Researcher Activity Profile

Research Author Detailed Information 

Angela Coxon Publication Rate By Year

Angela Coxon has published 1 paper(s) in 2006, 5 paper(s) in 2007, 3 paper(s) in 2008, for a total of 9 research publications in total.

Angela A Coxon Author Information

LAST NAME: coxon

FIRST NAME: angela

INITIALS: A

AFFILIATION:

Papers

Angela Coxon's Publication Record

1. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Year Published: 2006
Department of Oncology Research, Amgen, Inc., Thousand Oaks, CA 91320-1799, USA. tonyp@amgen.com
2. Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. Year Published: 2007
Chemistry Research and Discovery, One Amgen Center Drive Thousand Oaks, CA 91320, USA. celia.dominguez@chdi-inc.org
3. AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and Xenografts. Year Published: 2007
Authors' Affiliation: Department of Oncology Research, Amgen, Inc., Thousand Oaks, California.
4. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Year Published: 2007
Department of Oncology Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91362, USA. tjun@amgen.com
5. c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations. Year Published: 2008
Departments of Molecular Structure, Oncology Research, Pathology, and Medicinal Chemistry, Amgen Inc., Thousand Oaks, California 91320.
6. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Year Published: 2007
Department of Oncology Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91362, USA. tjun@amgen.com
7. Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. Year Published: 2007
Chemistry Research and Discovery, One Amgen Center Drive Thousand Oaks, CA 91320, USA. celia.dominguez@chdi-inc.org
8. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. Year Published: 2008
9. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. Year Published: 2008
Department of Molecular Structure, Amgen Inc., Thousand Oaks, CA 91320, USA.